ONCOtracker - About the company
ONCOtracker is a seed company based in West Hollywood (United States), founded in 2014 by James R Berenson. It operates as a Developer of immune assays for the diagnosis of cancer. ONCOtracker has raised $1.3M in funding. The company has 518 active competitors, including 137 funded and 113 that have exited. Its top competitors include companies like Guardant Health, Natera and Myriad Genetics.
Company Details
Developer of immune assays for the diagnosis of cancer. The company's diagnostic assay is used for testing multiple myeloma, B-cell malignancies and other related disorders. It includes Serum B-Cell Maturation Antigen (sBCMA) blood test assay, which is used to monitor the tumour and predict the therapeutic outcome of patients with multiple myeloma. It is used to treat chronic lymphocytic leukaemia, B-cell lymphoma and solid tumour.
- Website
- oncotracker.com
- Social
- Email ID
- *****@oncotracker.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2014
Location
West Hollywood, United States
Stage
Seed
Total Funding
$1.3M in 3 rounds
Latest Funding Round
Ranked
217th among 518 active competitors
Employee Count
5 as on Jun 30, 2026
Similar Companies
Sign up to download ONCOtracker's company profile
ONCOtracker's funding and investors
ONCOtracker has raised a total funding of $1.3M over 3 rounds. Its first funding round was on Nov 10, 2016.
Here is the list of recent funding rounds of ONCOtracker:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 13, 2020 | 5102260 | Seed | 7085748 | 2303832 | 1064030 | 6288083 |
Mar 13, 2019 | 8567412 | Seed | 6584830 | 2136456 | 6259415 | 9899967 |
Nov 10, 2016 | 1624806 | Seed | 3468404 | 9165779 | 5241603 | 1259895 |
Access funding benchmarks and valuations. Sign up today!View details of ONCOtracker's funding rounds and investors
ONCOtracker's founders and board of directors
Founder? Claim ProfileThe founders of ONCOtracker is James R Berenson. James R Berenson is the CEO of ONCOtracker.
Here are the details of ONCOtracker's key team members:
- James R Berenson: Founder & CEO of ONCOtracker.
View details of ONCOtracker's Founder profiles and Board Members
ONCOtracker's employee count trend
ONCOtracker has 5 employees as of Jun 26. Here is ONCOtracker's employee count trend over the years:
Uncover ONCOtracker's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ONCOtracker's Competitors and alternates
Top competitors of ONCOtracker include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of ONCOtracker, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 79/100 | |
2nd | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 77/100 | |
3rd | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 72/100 | |
4th | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 71/100 | |
5th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 70/100 | |
6th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 69/100 | ||
7th | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
8th | Crown Bioscience 2006, Santa Clara (United States), Acquired | Developer of drugs for cancer and CVMD (Cardiovascular and Metabolic Diseases) | $85.9M | 68/100 | |
9th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
10th | Alamar Biosciences 2018, Fremont (United States), Public | Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels | $250M | 66/100 | |
217th |  ONCOtracker 2014, West Hollywood (United States), Seed | Developer of immune assays for the diagnosis of cancer | $1.3M | - | 31/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ONCOtracker's competitors? Click here to see the top ones
ONCOtracker's Investments and acquisitions
ONCOtracker has made no investments or acquisitions yet.
Reports related to ONCOtracker
Here is the latest report on ONCOtracker's geography:
News related to ONCOtracker
•
•
OncoTracker Expands Multiple Myeloma Intellectual PropertyPR Newswire•Mar 12, 2019•ONCOtracker, Onco Tracker
•
Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition | Business WireBusiness Wire•Dec 06, 2017•Juno Therapeutics, Lilly, ONCOtracker, Fred Hutch and 2 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ONCOtracker
Explore our recently published companies
- Ludlowfitness - 2006 founded, Unfunded company
- Syracuseindoorsportscenter - Unfunded company
- Ultimateperformance - Unfunded company
- Calstreethockey - 1999 founded, Unfunded company
- Newkscc - 2011 founded, Unfunded company
- Justgrinding - Unfunded company
